﻿<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Aidsmap news - English</title>
    <description> </description>
    <link>http://www.aidsmap.com/Aidsmap-news-English/page/1260794/</link>
    <language>en-gb</language>
    <copyright>NAM Publications - 2012</copyright>
    <pubDate>Wed, 08 Feb 2012 08:48:19 GMT</pubDate>
    <lastBuildDate>Wed, 08 Feb 2012 08:48:19 GMT</lastBuildDate>
    <docs>http://backend.userland.com/rss</docs>
    <generator>RSS.NET: http://www.rssdotnet.com/</generator>
    <item>
      <title>Professional tattooing in sterile environment not associated with risk of hepatitis C</title>
      <description>Tattooing or body
piercing in professional parlours is not associated with an increased risk of
infection with hepatitis C virus, a literature review published in the online
edition of Clinical Infectious Diseases
shows. However, the authors did find evidence that tattooing in non-sterile
environments, such as prisons, was associated with the infection. They also
found isolated</description>
      <link>http://www.aidsmap.com/Professional-tattooing-in-sterile-environment-not-associated-with-risk-of-hepatitis-C/page/2234340/</link>
      <category>Hepatitis C transmission and prevention</category>
      <category>Injecting drug use</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Professional-tattooing-in-sterile-environment-not-associated-with-risk-of-hepatitis-C/page/2234340/</guid>
      <pubDate>Wed, 08 Feb 2012 06:30:00 GMT</pubDate>
    </item>
    <item>
      <title>New BHIVA guidelines recommend discussion with all patients on potential of HIV treatment to protect sexual partners</title>
      <description>The British HIV Association (BHIVA) today recommends that doctors
should discuss the evidence for the effectiveness of antiretroviral treatment as
prevention with all patients with HIV, and that it should be offered those who
want to protect their partners from the risk of HIV infection – even if they
have no immediate clinical need</description>
      <link>http://www.aidsmap.com/New-BHIVA-guidelines-recommend-discussion-with-all-patients-on-potential-of-HIV-treatment-to-protect-sexual-partners/page/2235411/</link>
      <category>Infectiousness and treatment as prevention</category>
      <category>Must see</category>
      <category>Starting treatment</category>
      <category>Treatment guidelines</category>
      <category>United Kingdom</category>
      <author>Keith Alcorn</author>
      <guid isPermaLink="True">http://www.aidsmap.com/New-BHIVA-guidelines-recommend-discussion-with-all-patients-on-potential-of-HIV-treatment-to-protect-sexual-partners/page/2235411/</guid>
      <pubDate>Mon, 06 Feb 2012 19:50:00 GMT</pubDate>
    </item>
    <item>
      <title>US CDC recommends HPV vaccine for young men</title>
      <description>Young men and adolescent boys between the ages of 11 and 21
should be vaccinated against human papillomavirus, the cause of genital warts,
anal and cervical cancer, the Advisory Committee on Immunization Practices has
recommended, in a new Adult Immunization Schedule published in Annals of Internal Medicine.
The committee also recommends that all gay</description>
      <link>http://www.aidsmap.com/US-CDC-recommends-HPV-vaccine-for-young-men/page/2235492/</link>
      <category>Immunisations</category>
      <category>Sexually transmitted infections</category>
      <category>Vaccines</category>
      <author>Keith Alcorn</author>
      <guid isPermaLink="True">http://www.aidsmap.com/US-CDC-recommends-HPV-vaccine-for-young-men/page/2235492/</guid>
      <pubDate>Mon, 06 Feb 2012 08:50:00 GMT</pubDate>
    </item>
    <item>
      <title>Gardasil protects against recurrence of pre-cancerous anal lesions in HIV-negative gay men</title>
      <description>The genital wart
vaccine Gardasil significantly
reduces the risk of high-grade pre-cancerous anal lesion recurrence in men who
have sex with men, US investigators report in the online edition of Clinical Infectious Diseases.
The vaccine reduced
the risk of lesion recurrence by approximately 50% in the first two years after
immunisation. There was some evidence that</description>
      <link>http://www.aidsmap.com/Gardasil-protects-against-recurrence-of-pre-cancerous-anal-lesions-in-HIV-negative-gay-men/page/2234343/</link>
      <category>Men who have sex with men (MSM)</category>
      <category>Sexually transmitted infections</category>
      <category>United States</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Gardasil-protects-against-recurrence-of-pre-cancerous-anal-lesions-in-HIV-negative-gay-men/page/2234343/</guid>
      <pubDate>Mon, 06 Feb 2012 08:30:00 GMT</pubDate>
    </item>
    <item>
      <title>For patients with HIV viral load is key in immune response to yellow fever vaccine</title>
      <description>Viral load is the only factor associated
with a poorer antibody response to the yellow fever vaccine in patients with
HIV, according to a French study published in the online edition of the Journal of Acquired Immune Deficiency
Syndromes.
For patients vaccinated after diagnosis
with HIV, an undetectable viral load was the “unique determinant” of</description>
      <link>http://www.aidsmap.com/For-patients-with-HIV-viral-load-is-key-in-immune-response-to-yellow-fever-vaccine/page/2229704/</link>
      <category>Health problems</category>
      <category>Immunisations</category>
      <category>Latin America</category>
      <category>Must see</category>
      <category>Sub-Saharan Africa</category>
      <category>Travel</category>
      <category>Western and Central Europe</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/For-patients-with-HIV-viral-load-is-key-in-immune-response-to-yellow-fever-vaccine/page/2229704/</guid>
      <pubDate>Thu, 02 Feb 2012 08:10:00 GMT</pubDate>
    </item>
    <item>
      <title>Contraception in HIV prevention trials: injectable hormonal methods more effective?</title>
      <description>Women
using injectable (hormonal) contraceptives had a significantly lower rate of
pregnancy compared to those using oral contraception in a major HIV prevention study, researchers report in the advance online edition of AIDS.
However, the same study also found that women who used an injectable hormonal contraceptive method were at higher risk of</description>
      <link>http://www.aidsmap.com/Contraception-in-HIV-prevention-trials-injectable-hormonal-methods-more-effective/page/2229312/</link>
      <category>Conception</category>
      <category>Contraception</category>
      <category>Sub-Saharan Africa</category>
      <author>Carole Leach-Lemens</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Contraception-in-HIV-prevention-trials-injectable-hormonal-methods-more-effective/page/2229312/</guid>
      <pubDate>Thu, 02 Feb 2012 07:10:00 GMT</pubDate>
    </item>
    <item>
      <title>Men who have sex with men may now be the highest-risk group for HIV in Africa, IAVI study suggests</title>
      <description>Men who have sex with men may now be at considerably higher
risk of acquiring HIV than other at-risk groups such as female sex workers or
young people of either sex, if findings by the International AIDS Vaccine
Initiative (IAVI) of HIV incidence at two centres in Kenya can be generalised to other
populations.
The</description>
      <link>http://www.aidsmap.com/Men-who-have-sex-with-men-may-now-be-the-highest-risk-group-for-HIV-in-Africa-IAVI-study-suggests/page/2234346/</link>
      <category>Epidemiology and behaviour</category>
      <category>Kenya</category>
      <category>Men who have sex with men (MSM)</category>
      <category>Sex workers</category>
      <category>South Africa</category>
      <author>Gus Cairns</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Men-who-have-sex-with-men-may-now-be-the-highest-risk-group-for-HIV-in-Africa-IAVI-study-suggests/page/2234346/</guid>
      <pubDate>Wed, 01 Feb 2012 11:30:00 GMT</pubDate>
    </item>
    <item>
      <title>HIV care providers in US struggling to cope with rising patient numbers</title>
      <description>HIV doctors in the US are struggling to
meet the demands of a rising patient caseload, according to the findings of a
national survey. 
Two-thirds of HIV treatment providers
reported an increase in patient numbers, and a third reported difficulties
being reimbursed for the care they provided. 
The second annual HealthHIV State of Primary</description>
      <link>http://www.aidsmap.com/HIV-care-providers-in-US-struggling-to-cope-with-rising-patient-numbers/page/2232782/</link>
      <category>Delivery of care</category>
      <category>Must see</category>
      <category>United States</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/HIV-care-providers-in-US-struggling-to-cope-with-rising-patient-numbers/page/2232782/</guid>
      <pubDate>Wed, 01 Feb 2012 08:40:00 GMT</pubDate>
    </item>
    <item>
      <title>Quarter of men resume sex before wounds from circumcision fully healed in Zambian study</title>
      <description>Approximately a quarter of men undergoing circumcision
resume sexual activity before their wounds have fully healed, Zambian research
published in the online edition of AIDS
shows. 
Most of the men reporting the early resumption of sexual
activity engaged in unprotected sex, often with multiple partners.
The investigators calculated that early resumption of sexual
activity at this</description>
      <link>http://www.aidsmap.com/Quarter-of-men-resume-sex-before-wounds-from-circumcision-fully-healed-in-Zambian-study/page/2227154/</link>
      <category>Circumcision</category>
      <category>Must see</category>
      <category>Zambia</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Quarter-of-men-resume-sex-before-wounds-from-circumcision-fully-healed-in-Zambian-study/page/2227154/</guid>
      <pubDate>Tue, 31 Jan 2012 09:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Raltegravir/Truvada HIV PEP regimen well tolerated with no infections after its use</title>
      <description>Raltegravir could have a “useful” role in HIV post-exposure
prophylaxis, according to investigators from the US writing in the online
edition of the Journal of Acquired Immune
Deficiency Syndromes. 
Doctors in Boston, Massachusetts, prescribed a post-exposure
prophylaxis (PEP) regimen of raltegravir (Isentress)
with tenofovir and FTC (Truvada) to
100 patients after possible sexual exposure to HIV.</description>
      <link>http://www.aidsmap.com/RaltegraviriTruvadai-HIV-PEP-regimen-well-tolerated-with-no-infections-after-its-use/page/2227321/</link>
      <category>Must see</category>
      <category>PEP</category>
      <category>United States</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/RaltegraviriTruvadai-HIV-PEP-regimen-well-tolerated-with-no-infections-after-its-use/page/2227321/</guid>
      <pubDate>Tue, 31 Jan 2012 08:10:00 GMT</pubDate>
    </item>
  </channel>
</rss>
